3rd Peptide-Based Therapeutics Summit 2026

Peptide therapies are rapidly becoming a disruptive modality, led by Merck’s oral PCSK9 inhibitor and Johnson and Johnson’s IL23R, with the hope to develop best-in-class drugs with improved chemistry, formulation and clinical efficacy.
 
To shine a light on the progress of this field, the highly anticipated 3rd Peptide-Based Therapeutics Summit returns to Boston as the industry’s only dedicated platform to turbocharge the next generation of peptide discoveries through development and towards life-saving treatments.
 
Gathering industry leaders including Parabilis Medicines, Circle Pharma, Abbvie, Merck, Chugai Pharmaceuticals and many more, this is your premium forum to explore:
 
- Novel computational tools
- Optimize analytical assays
- Formulating cell-specific delivery methods
- DMPK translatability towards clinical success of peptide therapies
 
Join 100+ stakeholders from CEOs to Scientists in disciplines ranging from peptide drug discovery R AND D, medicinal chemistry, pharmacology and formulation to accelerate this goldilocks modality from concept to commercialization.